/ /

Fred Gebhart
Allergan building presence in glaucoma with implant and MIGS device
Allergan is moving forward with plans to introduce innovative drug delivery device and surgical device for glaucoma
Device makers swing for fence with new technologies
Device manufacturers presenting new implants and technologies to treat glaucoma. As the industry moves from 1.0 devices to 2.0 devices, this will be a transformative time in the way physicians treat patients.
FDA making changes in approval processes for industry, patients
The laws governing ophthalmic drug and device approvals have changed little in recent years. But the FDA is making significant and far-reaching changes in its approvals process.
Three companies on the “Horizon” with glaucoma drugs
The pace of new glaucoma drug development continues, fueled by continuing research into novel mechanisms of action. Three companies, Aerie Pharmaceuticals, Bausch + Lomb, and Inotek Pharmaceuticals, shared their latest results.
B + L dedicated to eye care with strong portfolio, new programs
Bausch + Lomb (B + L) outlines the company's commitment to eye care with a strong portfolio, new programs, patient access, and better pricing.
New approaches and technologies offer hope in vision restoration
New agents and devices offer promise to control IOP and slow, perhaps even stop, the advancing vision loss that is common in glaucoma. Research and development to restore vision is starting to show significant results in preclinical models and early stage clinical trials.
Drug-delivery platforms offer more options and promise for clinicians
Seven glaucoma drug delivery companies reviewed the latest data on platforms
Early response to anti-VEGF therapy predictive of longer-term results
A new analysis of an old study suggests that early response to agents that block vascular endothelial growth factor can predict longer-term improvement in visual acuity in patients with DME.
Provider status
With provider status now a reality in 38 states, HR 592 and S 314 have powerful Congressional support. How long before the payers come on board?
Consider latest excimer laser techniques for presbyopia
Excimer laser ablations to the cornea (PresbyLASIK) to create a multifocal cornea may be an alternative treatment for patients with presbyopia

Poll

View Results